• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B3 filed by Atlantic International Corp.

    8/22/25 4:05:31 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ATLN alert in real time by email
    424B3 1 ea0253792-424b3_atlantic.htm PROSPECTUS SUPPLEMENT

    Filed Pursuant to

    Rule 424(b)(3) under the

    Securities Act of 1933
    Registration No. 333-280653

     

    PROSPECTUS SUPPLEMENT

    Dated August 22, 2025

    (To Prospectus Dated July 22, 2024)

     

    ATLANTIC INTERNATIONAL CORP.

     

    13,711,743 Shares of Common Stock

     

    This prospectus supplement (the “Sticker Supplement”) modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, our Prospectus filed with the SEC dated July 22, 2024 (the “Prospectus”), related to the offer and resale of up to an aggregate of 13,711,743 shares of common stock par value $0.00001 per share held by Selling Shareholders set forth under the title “Selling Shareholders”.

      

    This Sticker Supplement is not complete without, and may not be delivered or used except in connection with, the Prospectus.

     

    Our shares of common stock are quoted on the NASDAQ Capital Market under the symbol “ATLN.” On August 21, 2025, the last reported sale price of our common stock on the NASDAQ Capital Market was $3.96 per share.

     

    The information contained in this Sticker Supplement modifies and supersedes, in part, the information in the Prospectus. Any information that is modified or superseded in the Prospectus shall not be deemed to constitute a part of the Prospectus, except as modified or superseded by this Sticker Supplement.

     

    We may amend or supplement the Prospectus from time to time by filing amendments or supplements as required. You should read the entire Prospectus, and any amendments or supplements carefully before you make an investment decision.

     

    Investing in our securities involves risks. See “Risk Factors” beginning on page 4 of the Prospectus and in documents incorporated by reference into the Prospectus.

     

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Sticker Supplement, or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

     

    FORWARD-LOOKING STATEMENTS

     

    You should carefully consider the risk factors set forth in the Prospectus, as well as the other information contained in or incorporated by reference into this Sticker Supplement and the Prospectus. This Sticker Supplement and the Prospectus and documents incorporated therein by reference contain forward-looking statements regarding events, conditions, and financial trends that may affect our plan of operation, business strategy, operating results, and financial position. You are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Actual results may differ materially from those included within the forward-looking statements as a result of various factors. Cautionary statements in the “Risk Factors” section of the Prospectus and in documents incorporated by reference into the Prospectus identify important risks and uncertainties affecting our future, which could cause actual results to differ materially from the forward-looking statements made or included in this Sticker Supplement and the Prospectus.

     

     

     

     

    AMENDED SELLING SHAREHOLDERS TABLE

     

    On July 22, 2024 we filed a Prospectus in accordance with Rule 424(b)(3) of the Securities Act of 1933, as amended. The Prospectus included 4,704,098 Shares to be held in escrow for the legacy shareholders of the Company who may be issued shares pursuant to a Settlement Offer which has now expired. This Sticker Supplement is being filed to disclose the following: The Board of Directors authorized the release of shares in the aggregate amount of 1,681,860 shares from the shares held in escrow to: Perri Sason (250,000 shares), Jasck Bessman (134,000 shares), Ofer E. Gabby Irrevocable Trust (33,000 shares), Jeffrey Jagid (1,000,000 shares) and Michael Tenore (264,860 shares), as set forth in the attached Selling Shareholders table.

     

    The date of this Sticker Supplement to Prospectus is August 22, 2025.

     

    2

     

     

    SELLING SHAREHOLDERS

     

    The Shares offered by the Selling Shareholders include those issued to the Selling Shareholders pursuant to the Merger Agreement and as Merger Consideration (as defined in the Merger Agreement) or otherwise. For additional information regarding the issuances of the Shares, see “Description of the Shares” above. We are registering the Shares in order to permit the Selling Shareholders to offer the shares for resale from time to time. 

     

    The table below lists the Selling Shareholders’ information regarding the beneficial ownership of the shares of common stock. The second column lists the number of shares of common stock beneficially owned by the Selling Shareholders, based on their ownership of the Shares, as of the date of this prospectus supplement.

     

    In accordance with the terms of a registration rights agreement with the Selling Shareholders under the Merger Agreement, this prospectus generally covers the resale of the maximum number of Shares.

      

    The Selling Shareholders may sell all, some or none of its shares in this offering. See “Plan of Distribution.”

     

     

    Names and Address of Selling Shareholders

      Number of
    Shares of
    Common
    Stock
    Beneficially
    Owned Prior
    to Offering
       Maximum
    Number of
    Shares of
    Common
    Stock to be
    Sold Pursuant
    to this
    Prospectus
       Number of
    Shares of
    Common
    Stock Owned
    After 
    Offering
     
    Alan Hartley  71 Alba Road Wellesley, Massachusetts 02481   1,038,559    1,038,559    -0- 
    Pequod Consulting LLC(1)  Hankins Waterfront Plaza, Suite 556 Main Street Charlestown Nevis   2,696,610    2,696,610    -0- 
    Adam Raymond Jones  12 Wergs Hau Road Wolverhampton West Midlands WV69DA United Kingdom   1,038,136    1,038,136    -0- 
    Lucas William Jones  5 Orchard Grove Four Oaks, Sutton Coldfield Birmingham, B74 4AX United Kingdom   1,548,728    1,548,728    -0- 
    Raymond William Jones and Katrina Jones JT  12 Wergs Hau Road Wolverhampton West Midlands WV69DA United Kingdom   1,385,594    1,385,594    -0- 
    Gabbay Investment  128 Summit Ave Hackensack, New Jersey 07601   33,797    33,797    -0- 
    Ofer E. Gabbay Irrevocable Trust  3000 Island Blvd, Apt. 2903, Aventura FL 33160   33,000    33,000    -0- 
    Perri Sason  1415 Sunset Harbour Drive, Apartment 406 Miami Beach, Florida 33139   536,500    536,500    -0- 
    Jack Bressman  160 West 22nd Street, Apartment 603 New York, New York 10011   420,500    420,500    -0- 
    John and Susan Linn  20 Gledholdt Road Huddersfield HD1 4HP   338,984    338,984    -0- 
    Daniel Llovet  12 Bush Bach Tredegar Blaenau Gwent NP22 3SR Wales United Kingdom   254,237    254,237    -0- 
    Joshua Jagid  38 Rodney Place
    Demarest, New Jersey 07629
       100,000    100,000    -0- 
    Jeffrey Jagid(2) 

    c/o Atlantic International Corp.

    270 Sylvan Avenue, Ste. 2230

    Englewood Cliffs, NJ 07632

       

    4,335,169

        

    1,000,000

        

    3,335,169

     
    Michael Tenore(3) 

    c/o Atlantic International Corp.

    270 Sylvan Avenue., Ste. 2230

    Englewood Cliffs, NJ 07632

       

    1,266,494

        

    264,860

        

    1,001,634

     
       TOTAL:               

     

    1Pequod Consulting LLC has acted as a consultant to the Company since October 15, 2022. Upon the Closing of the Merger on June 18, 2024, the Company retained Pequod’s services under a two-year Consulting Agreement.

     

    2 Mr. Jagid is Chief Executive Officer and a Director of the Company.
       
    3 Mr. Tenore is General Counsel of the Company.

     

    3

     

     

    Get the next $ATLN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATLN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATLN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Broderick Christopher bought $58 worth of shares (577,171 units at $0.00), increasing direct ownership by 40% to 2,004,237 units (SEC Form 4)

    4/A - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    6/25/25 5:11:34 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Executive Officer Jagid Jeffrey M bought $289 worth of shares (2,885,856 units at $0.00), increasing direct ownership by 340% to 3,735,169 units (SEC Form 4)

    4/A - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    6/25/25 5:04:40 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: General Counsel Tenore Michael bought $58 worth of shares (577,171 units at $0.00), increasing direct ownership by 136% to 1,001,634 units (SEC Form 4)

    4/A - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    6/25/25 5:02:59 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ATLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Broderick Christopher

    4 - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    8/15/25 5:10:50 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by General Counsel Tenore Michael

    4 - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    8/13/25 4:46:32 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Executive Officer Jagid Jeffrey M gifted 400,000 shares, decreasing direct ownership by 11% to 3,335,169 units (SEC Form 4)

    4 - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    8/13/25 4:45:41 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ATLN
    SEC Filings

    View All

    SEC Form 424B3 filed by Atlantic International Corp.

    424B3 - ATLANTIC INTERNATIONAL CORP. (0001605888) (Filer)

    8/22/25 4:05:31 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13D/A filed by Atlantic International Corp.

    SCHEDULE 13D/A - ATLANTIC INTERNATIONAL CORP. (0001605888) (Subject)

    8/15/25 4:05:06 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form RW filed by Atlantic International Corp.

    RW - ATLANTIC INTERNATIONAL CORP. (0001605888) (Filer)

    7/14/25 4:05:04 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ATLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Atlantic International Corp. to Present at the 2025 Gateway Conference on September 4

    ENGLEWOOD CLIFFS, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Atlantic International Corp. (NASDAQ:ATLN), a rapidly expanding provider of workforce solutions and outsourced services, today announced that its CEO will present at the 2025 Annual Gateway Conference, one of the nation's premier investor events connecting high-growth companies with institutional investors, analysts, and capital markets professionals. The conference will take place September 4–5, 2025, at the Four Seasons Hotel in San Francisco, CA. Jeffrey Jagid, Atlantic International Corp.'s CEO, is scheduled to present on Thursday, September 4 at 9:00 a.m. Pacific Time (PT). The presentation will be webcast live and ava

    8/18/25 7:00:00 AM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Atlantic International Corp. Reports Strong Operational Improvements in Second Quarter 2025

    ENGLEWOOD CLIFFS, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Atlantic International Corp. (NASDAQ:ATLN), a leading strategic staffing, outsourced services, and workforce solutions company, today announced financial results for the second quarter ended June 30, 2025, demonstrating significant operational improvements and a strengthened financial position. Second Quarter 2025 Highlights: Net loss narrowed by 81% to $10.7 million (or $0.20 per share), compared to a net loss of $54.9 million (or $1.96 per share) in Q2 2024Service revenue was $102.9 million, with permanent placement services up 17% year-over-year.Gross profit margin improved to 11.1%, reflecting pricing discipline and efficiency

    8/14/25 7:00:00 AM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gateway Group Announces Preliminary Sponsors and Presenting Companies for 2025 Gateway Conference

    NEWPORT BEACH, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Gateway Group ("Gateway"), a leading financial communications and digital media advisory firm, today announced the initial sponsors and presenting companies confirmed for its annual Gateway Conference taking place at the Four Seasons Hotel in San Francisco on September 3rd and 4th. The conference is expected to host more than 300 institutional investors and analysts for two days of company presentations and curated one-on-one meetings with executives from high-growth public and private companies across the tech, AI, cleantech, consumer, financial services, and industrials sectors. "We appreciate the strong support from our sponsors

    7/30/25 8:30:00 AM ET
    $ACNT
    $AIRG
    $AKA
    Steel/Iron Ore
    Industrials
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ATLN
    Leadership Updates

    Live Leadership Updates

    View All

    $ATLN
    Financials

    Live finance-specific insights

    View All

    Atlantic International Corp. Appoints Industry Veteran Matt Evelt as Chief Operating Officer to Lead Global Workforce Solutions Strategy

    ENGLEWOOD CLIFFS, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Atlantic International Corp. (NASDAQ:ATLN), a premier provider of outsourced services, staffing, and workforce solutions, today announced the appointment of Matt Evelt as Chief Operating Officer (COO), effective immediately. Evelt brings more than two decades of leadership experience in workforce strategy, operational transformation, and international expansion. In his new role, he will oversee global operations, drive efficiency, and help scale Atlantic International's delivery of innovative, client-focused staffing and workforce solutions. Evelt most recently served as President – Americas at Airswift, where he successfully led

    6/2/25 1:05:49 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Atlantic International Corp. Reports Strong 2024 Results with Over $442 Million in Revenue; Over 10% Revenue Growth

    Company Completes First Quarter Publicly-Traded on Nasdaq Global Market under "ATLN" Announces Strategic Developments and Outlook; Targets $1 to $1.5 Billion Revenue from Both Organic Growth and M&A Initiatives in the Next 12 to 18 Months ENGLEWOOD CLIFFS, N.J., March 28, 2025 (GLOBE NEWSWIRE) -- Atlantic International Corp. ("Atlantic" or the "Company") (NASDAQ:ATLN), a leading provider of strategic staffing, outsourced services and workforce solutions, today announced its financial results for the fourth quarter and full year ended December 31, 2024. Key Financial Highlights: Q4 2024 Revenue: Revenue for the fourth quarter was $129.5 million, representing an 11.5% increase from $116.

    3/28/25 7:30:00 AM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials